
EDCTP and CEPI funding moves IAVI’s Lassa fever vaccine candidate into advanced clinical development
Sierra Leone Telegraph: 17 June 2021: IAVI has announced it has received an award of €22.8 million from the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct a Phase 2b clinical trial of a novel vaccine candidate to prevent Lassa [Read More]